Conductance of alveolar capillary membrane (D M ) and capillary blood volume (V C ) are the subcomponents of the pulmonary diffusing capacity for carbon monoxide (DLCO). In chronic heart failure, stress failure of the membrane provides a mechanism for reduced D M and subsequent impairment of DLCO. Angiotensin-converting enzyme inhibition improves DLCO in patients with chronic heart failure. This study was aimed at investigating which of the two subcomponents of DLCO is affected by angiotensin-converting enzyme inhibitors. Twenty-seven patients with NYHA class II to III chronic heart failure (group 1) and 13 age-and sex-matched normal subjects underwent pulmonary function testing with determination of D M and V C , while receiving placebo and 48 h and 1 and 2 months after starting enalapril treatment (10 mg twice daily). Nine similar patients (group 2) received isosorbide dinitrate (40 mg thrice daily) for a month then enalapril for another month, and underwent pulmonary function testing at 48 h and 1 month after starting treatments. Effects of angiotensin-converting enzyme inhibition in normal controls were not significant in the short-or mid-term. In group 1 patients, the only change observed at 48 h was a reduction in V C (probably due to a decrease in capillary pulmonary pressure). There was a marked increase in D M to a similar extent at 1 and 2 months, resulting in a significant improvement in DLCO despite a decrease in V C . In group 2 patients, nitrates failed to improve DLCO and D M , whereas enalapril was as effective as in group 1. These observations suggest a modulatory effect of angiotensin-converting enzyme inhibition on the membrane function which emerges gradually and persists over time and is probably dissociated from changes in pulmonary capillary pressure and V C . Chronic heart failure disturbs the alveolar capillary interface and increases gas diffusion resistance ; angiotensin-converting enzyme inhibition restores the diffusive properties of the membrane and gas transfer, and protects the lung when the heart is failing.
INTRODUCTION
Exercise intolerance in chronic heart failure has long been ascribed to cardiac and peripheral factors [1, 2] , including Key words : enalapril, pulmonary capillary blood, pulmonary function.
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Correspondence : Dr M. Guazzi. blood vessels [3, 4] and skeletal muscles [5, 6] . Studies that focus primarily on pulmonary pathophysiology in this syndrome are limited. Only recently have pulmonary factors been suggested as important determinants of the debilitating symptoms [7, 8] . A reduction in resting pulmonary diffusing capacity of carbon monoxide (DLCO) in chronic heart failure has been documented [9] [10] [11] [12] and proposed as being an independent predictor of peak exercise oxygen uptake [7, 11] in these patients.
DLCO may be divided into two subcomponents [13, 14] : D M , the molecular diffusion of carbon monoxide across the alveolar-capillary membrane ; and V C , the chemical reaction (θ) of carbon monoxide with pulmonary capillary blood. Because a proportion of the total diffusive resistance in heart failure is caused by reduced D M [11, 15] , the hypothesis has been advanced that proliferation of alveolar cells, thickening of the alveolar capillary interstitium and some fibrotic changes in response to a sustained pressure-induced trauma in the pulmonary microvasculature, may augment the thickness of alveolar capillary membrane and reduce D M [11] .
The observation that enalapril causes a significant increase of DLCO in patients with chronic heart failure [16] prompted us to investigate which of the two DLCO subcomponents is affected by enalapril, because an improvement in the D M component would reflect an ability of angiotensin-converting enzyme (ACE) inhibitors to specifically reverse or attenuate alterations in the alveolar capillary membrane that are associated with a failing heart.
PATIENTS AND METHODS

Patients and controls
The study population was composed of patients referred to the Institute of Cardiology, University of Milan, between December 1995 and May 1998 for evaluation of chronic heart failure. The cause of the disease was either idiopathic cardiomyopathy (cardiac enlargement and absence of a specific cause for cardiac failure) or ischaemic heart disease (documented previous myocardial infarction). Inclusion criteria were (1) willingness to participate in the study, (2) chronic stable NYHA functional class II to III due to cardiac dysfunction, (3) left ventricular ejection fraction 40 %. Exclusion criteria were (1) current or past history of smoking (more than 10 cigarettes per day during one of the past 5 years), (2) history of respiratory disease, (3) ACE inhibitor therapy, acetylsalicylic acid or other cyclo-oxygenase inhibitors within the last 6 months, (4) evidence of airway obstruction (FEV ".! to V C ratio 70 %, where FEV " n ! is the forced expiratory volume in 1n0 s).
The protocol was approved by the Ethics Committee of the Institute of Cardiology, University of Milan, and informed consent was obtained from each patient.
Forty patients were enrolled into the study. All were receiving optimal doses of frusemide and digoxin that had remained unaltered in the previous 2 months and were continued through the trial. Seven healthy individuals and six subjects with mild untreated primary hypertension, with no history of cardiorespiratory disease, with normal physical examination and chest X-ray, who were of a similar age and sex to the patients, did not smoke and were not taking cyclo-oxygenase inhibitors (patients and controls were carefully questioned concerning medications that might contain aspirin, and platelet aggregation was tested and found to be normal in all), volunteered to serve as controls. None of the patients and control subjects had participated in previous studies in our laboratory.
Left ventricular ejection fraction was assessed at rest, in the supine position by two-dimensional echocardiography according to Simpson's rule.
Standard colour Doppler velocimetry was used to measure the degree of mitral regurgitation, which was graded subjectively on a scale from none (0) to severe (5) .
Pulmonary function testing
Measurements of FEV ".! , vital capacity, mean voluntary ventilation and total lung capacity were made with Sensor Medics 2200 Pulmonary Function Test System. DLCO was measured in triplicate with washout intervals of at least 4 min (the average was taken as the final result), in the sitting position, with a standard single-breath technique [14] , using as a test gas 0.28 % carbon monoxide (CO). Measured diffusing capacity was corrected for the subject's haemoglobin concentration by the equation of Cotes et al. [17] . The single-breath alveolar volume (VA) was derived by methane dilution. Alveolar capillary membrane diffusing capacity (D M ) and the capillary volume of blood available for gas exchange (V C ) were determined, with the same equipment, according to the classic method of Roughton and Forster [13, 14] .
Study design
Patients were separated into group 1 (the first 30 consecutive patients enrolled) and group 2 (the last 10 consecutive patients enrolled). Three patients in group 1 and one in group 2 and controls did not complete the study (due to non-compliance with appointments and drugs, or for administrative reasons) and were excluded from the final result analysis. Patients in group 1 and controls received, in a single-blind fashion, placebo for 1 week and then enalapril (10 mg twice daily) for 2 months. Pulmonary function tests were performed at the beginning and at the end of the run-in, the former being utilized for screening patients with FEV " \V C 70 % and the latter as baseline values. Tests were repeated 48 h and 1 and 2 months after starting enalapril, 3 h after a light meal at the same time of the day. The present protocol was chosen in an attempt to monitor the beginning and persistence of effects of enalapril. Patients in group 2 received, in a single-blind fashion, placebo for 1 week, then isosorbide dinitrate (40 mg thrice daily) for a month and then, after a 3-day washout, enalapril (10 mg twice daily) for a month. Pulmonary function tests were performed during the run-in, as described, and repeated 48 h and a month after starting nitrates and after starting enalapril.
Data analysis
Data from patients and controls were compared by unpaired t-test and one-way ANOVA. The significance of differences between serial measurements was assessed by repeated-measures ANOVA and Newman-Keuls multiple comparison procedure. Differences at P 0.05 were considered statistically significant. Results are expressed as meanspS.D.
RESULTS
The anthropometric, circulatory, respiratory and therapeutic data of group 1 and 2 patients and controls are summarized in Table 1 . Pulmonary function and circulatory values reported were those recorded at the end of run-in and were similar to those at the beginning of , vital capacity, total lung capacity, DLCO and D M were lower and V C was greater in the two patient groups compared with control subjects. In heart failure, the proportion of diffusive resistance pertaining to the alveolar capillary membrane (DLCO\D M ) was similar in groups 1 and 2 and was greater than that in normal subjects. The reduction in D M was still evident when lung volume was taken into account by plotting D M \VA. Figures 1 and 2 and Table 2 report the results of spirometry with enalapril in group 1 patients and controls. ACE inhibition had no effects in control subjects, with respect to DLCO, its two subcomponents and lung volumes. In patients with heart failure, however, changes were recorded at 1 and 2 months, which consisted of a significant increase in DLCO, in diffusion across the alveolar capillary membrane (D M ) and in the alveolar capillary membrane diffusing capacity per unit effective alveolar volume (D M \VA), and of a decrease in the volume of blood available for gas exchange (V C ) and in the proportion of the total diffusive resistance related to the alveolar capillary membrane (DLCO\D M ). As for the lung volumes, FEV ".! and mean voluntary ventilation were augmented, vital and total lung capacities were unchanged compared with placebo. Interestingly (i) none of the changes described were detected at 48 h of active ACE inhibition, except a significant reduction of V C , and (ii) changes recorded at 1 month persisted at 2 months. Table 3 reports the respiratory data in group 2 patients and shows that, compared with placebo, values were similar, while on isosorbide dinitrate, both at 48 h and after 1 month of therapy ; on the contrary, DLCO and D M were significantly raised and V C significantly reduced after 1 month of enalapril, compared with both placebo and the corresponding nitrate values.
DISCUSSION
That heart failure may be associated with an increased lung diffusive resistance has long been known to pathophysiologists and clinicians [15] . More recent reports have proven that the depressed alveolar capillary membrane diffusing capacity is the major determinant of the excessive diffusive resistance [11] , and impaired pulmonary gas transfer correlates with exercise capacity and functional status in chronic heart failure [7, 11, 12, 16, 17] . Our previous observations have also shown that in this syndrome a modulation of pulmonary gas transfer is feasible with ACE inhibitors [16] . The present results provide the following additional information : ACE inhibition is effective on D M , the molecular diffusion of carbon monoxide across the alveolar capillary membrane, resulting in an improvement in DLCO even with a decreased V C ; this action is detectable in patients with heart failure and not in normal individuals, suggesting that alterations related to the syndrome are the substrate for the enalapril activity ; the effect is not immediate (in fact, it was not detectable at 48 h), but emerges gradually over time [18] , is persistent (results at 2 months were similar to those at 1 month) and is not duplicated by nitrates.
Diffusing capacity depends on (1) the exchange area (lung volume and capillary blood volume available for gas exchange), (2) the distance between capillaries and alveoli [9] (which is mainly related to the hydrostatic and osmotic forces governing transition of fluid from the (1 month) 3.15p0.5F 3.1p0.9 98p25F 3.9p1.2 24.5p2.9*F 32.7p8.4*F 99p12*F intravascular to the extravascular phase), (3) the structural and functional properties of the alveolar capillary membrane. The diminished lung volume, which is a common feature of chronic heart failure [8] , would decrease the exchange area. However, improvement in D M , which persisted even when effective alveolar volume was accounted for (D M \VA), and steadiness of vital and total lung capacities during treatment with enalapril, do not explain the diminished alveolar capillary membrane diffusive resistance on the basis of variations in the gas exchange area. The raised diastolic pressure in a dysfunctioning left ventricle is the initiating hydrostatic force for an increased fluid filtration in the lung interstitial space [19] and has been interpreted as a reason for the impairment of DLCO in heart failure [12] . Invasive procedures in our patients were not included in the protocol approved by the ethics committee. There are, however, some considerations that do not suggest a reabsorption of extravascular fluid volume as the main determinant of the increase in D M with ACE inhibition : patients were receiving optimal doses of frusemide and did not present with physical signs of fluid retention and lung congestion ; significant changes in DLCO did not occur at 48 h even though the hydrostatic forces that underlie the extravascular fluid accumulation diminish within a few hours after 10 mg of oral enalapril [20] . Results in this study point in the direction of a derangement of the alveolar capillary membrane. Elevation of pulmonary capillary pressure, as occurs in heart failure, may produce vascular and alveolar epithelial damage [8] , stress failure and dysfunction [21] of the alveolar capillary membrane. A persistent restraint of the inciting stimulus, i.e. the elevated hydrostatic pressure as an explanation for the benefits of ACE inhibitors, would imply that all agents which lower the pulmonary capillary pressure are also able to modulate the reduced diffusive conductance across the alveolar capillary membrane. However, short-term hydralazine and isosorbide dinitrate do not produce such an effect [16] ; DLCO is reported to decline after heart transplantation and to be stable after medical treatment of heart failure [22] and, even more convincing, enalapril was able to improve D M and DLCO in the same patients (group 2) in whom isosorbide dinitrate had failed, even though the reducing effect on V C was similar, suggesting a comparable lowering influence on the pulmonary capillary pressure.
At cardiac level, when an altered load and stretch of myocytes stimulates mitosis of cardiac fibroblasts, the renin-angiotensin-aldosterone system participates in the collagen synthesis and excessive collagen accumulation. In these circumstances, ACE inhibitors can protect the heart by inhibiting the angiotensin-mediated synthesis of collagen and by impeding its turnover through activation of the prostaglandin system [23] . That this protection may also be at work at the lung level is an attractive hypothesis. The gradual emergence over time of the restored diffusive properties is in keeping with this interpretation. Lung biopsies before and after treatment in a few patients were discouraged by the Institution Ethics Committee, even though they were desirable to strengthen this hypothesis.
In conclusion, this study documents that heart failure is associated with an impeded alveolar capillary interface resulting in excessive diffusive resistance ; ACE inhibition restores the alveolar capillary membrane properties and the pulmonary gas transfer, thus proving capable of protecting the lung from derangements due to the failing heart.
